The fact that Cytodyn’s leadership team flew out to ESMO and Munich does not necessarily mean that something major will happen. That being said, the conference doesn’t end until Saturday. OTOH, all those people didn’t fly to Germany for no reason. Flights, hotels, food, and incidentals cost precious funds.

Dr. Jay has shown himself to be methodical and rigorous. He backs and fills to shore up weaknesses and tries to turn them into strengths. Shareholders, especially those of us who have been here for years (a decade or longer), understandably want to be rewarded for their patience. However, it appears that ESMO may be another interim step; perhaps one leading to Europe and the rest of the world.

Reading the interpretations of the research so many here have provided reminds me of how difficult it is to bring a drug to market. Cytodyn is not only developing a medication, but a pathway to oncological treatment that has been unavailable. And, if I’m understanding your posts accurately, a means to addressing inflammation itself in multiple etiologies. This kind of Big Science takes time and lots of money. Maybe we’ll hear that they brought home some of those funds necessary for the next steps.